Compare Stocks

→ The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARMP Armata Pharmaceuticals	$2.76 +9.1%	$0.00	$1.07 ▼ $5.26	$99.77M	0.85	16,977 shs	9,511 shs
MTFB MOTIF BIO PLC/S	$0.11	$0.10	$0.08 ▼ $11.50	N/A	N/A	N/A	867,698 shs
OVB Overlay Shares Core Bond ETF	$19.93 +0.9%	$20.51	$18.69 ▼ $21.59	$47.83M	0.25	17,724 shs	11,563 shs
PAS Pascal Biosciences	C$0.02 -25.0%	C$0.02	C$0.02 ▼ C$0.10	C$984K	1.51	52,289 shs	4,000 shs

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARMP Armata Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
MTFB MOTIF BIO PLC/S	0.00%	0.00%	0.00%	0.00%	0.00%
OVB Overlay Shares Core Bond ETF	-0.83%	-0.53%	-5.21%	-3.63%	-5.16%
PAS Pascal Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%

The Next Step of Their Control Is Here … (Ad)

Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.

4 simple steps to protect your privacy and money before it’s too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARMP Armata Pharmaceuticals	3.1425 of 5 stars	3.5	5.0	0.0	0.0	2.8	1.7	0.6
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OVB Overlay Shares Core Bond ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PAS Pascal Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARMP Armata Pharmaceuticals	3.00	Buy	$7.00	153.62% Upside
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A
OVB Overlay Shares Core Bond ETF	0.00	N/A	N/A	N/A
PAS Pascal Biosciences	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest PAS, OVB, ARMP, and MTFB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/22/2024	ARMP Armata Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARMP Armata Pharmaceuticals	$4.53M	22.03	N/A	N/A	($0.89) per share	-3.10
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A	N/A
OVB Overlay Shares Core Bond ETF	N/A	N/A	N/A	N/A	N/A	N/A
PAS Pascal Biosciences	N/A	N/A	C$0.00 per share	55.00	C($0.02) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARMP Armata Pharmaceuticals	-$69.04M	-$1.98	N/A	N/A	N/A	-1,524.51%	-280.95%	-52.61%	5/9/2024 (Estimated)
MTFB MOTIF BIO PLC/S	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
OVB Overlay Shares Core Bond ETF	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PAS Pascal Biosciences	N/A	-C$0.01	N/A	∞	N/A	N/A	N/A	-340.40%	N/A

Latest PAS, OVB, ARMP, and MTFB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/21/2024	Q4 2023	ARMP Armata Pharmaceuticals	N/A	-$0.55	-$0.55	-$0.55	$0.68 million	$1.53 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARMP Armata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A
OVB Overlay Shares Core Bond ETF	$0.95	4.77%	N/A	N/A	N/A
PAS Pascal Biosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARMP Armata Pharmaceuticals	N/A	1.16	1.16
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A
OVB Overlay Shares Core Bond ETF	N/A	N/A	N/A
PAS Pascal Biosciences	882.79	0.03	0.17

Ownership

Institutional Ownership

Company	Institutional Ownership
ARMP Armata Pharmaceuticals	3.57%
MTFB MOTIF BIO PLC/S	N/A
OVB Overlay Shares Core Bond ETF	N/A
PAS Pascal Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ARMP Armata Pharmaceuticals	85.50%
MTFB MOTIF BIO PLC/S	N/A
OVB Overlay Shares Core Bond ETF	N/A
PAS Pascal Biosciences	15.43%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ARMP Armata Pharmaceuticals	66	36.15 million	5.24 million	Not Optionable
MTFB MOTIF BIO PLC/S	7	N/A	N/A	Not Optionable
OVB Overlay Shares Core Bond ETF	147,000	2.40 million	N/A	Not Optionable
PAS Pascal Biosciences	6	65.59 million	N/A	Not Optionable

PAS, OVB, ARMP, and MTFB Headlines

Source	Headline
	Edwards gets Q1 boost as Pascal valve repair sales ramp up medtechdive.com - April 26 at 2:01 PM
	Pacers' Pascal Siakam has been a matchup nightmare for Bucks msn.com - April 26 at 9:01 AM
	NBA Playoff Props: Will Pascal Siakam Keep Up Historic Playoff Start? msn.com - April 26 at 9:01 AM
	Pascal Siakam entered the playoffs wanting to be the Indiana Pacers leader. He left Milwaukee on top of the league. si.com - April 25 at 2:53 PM
	Pascal Siakam shouts out Pacers fans after monster Game 2 outing vs. Bucks msn.com - April 24 at 3:47 PM
	This is why Pacers traded for Pascal Siakam: Spicy P has been best player not named Jokic in 2024 NBA Playoffs sportingnews.com - April 24 at 3:47 PM
	Pascal Siakam 6th NBA Player to Record These Stats in Playoff Game With 0 Turnovers basketballinsiders.com - April 24 at 3:47 PM
	Pascal Siakam NBA Playoff history, stats, appearances and record ftw.usatoday.com - April 24 at 10:47 AM
	Pascal Siakam provides Pacers steadying force and voice with 37 points in Game 2 win msn.com - April 24 at 10:47 AM
	How Pascal Siakam’s voice — and game —led the Pacers to evening series with Bucks usatoday.com - April 24 at 10:47 AM
	Pascal Siakam Player Prop Bets: Pacers vs. Bucks \| April 26 sportsbookwire.usatoday.com - April 24 at 10:47 AM
	Pascal Siakam leads Pacers offense in win, evens series with Bucks wishtv.com - April 24 at 5:47 AM
	Brighton's Pascal Gross is 'best player I have played with' theargus.co.uk - April 24 at 5:47 AM
	Pascal Siakam Reaches Wilt Chamberlain Territory With Dominant Playoff Start givemesport.com - April 24 at 5:47 AM
	Pacers forward Pascal Siakam discusses his 37-point out in a win over the Bucks in Game 2. indystar.com - April 24 at 5:47 AM
	Pascal Siakam helps the Pacers tie serires up at 1-1 against Bucks hoopshype.com - April 24 at 12:29 AM
	Pascal Siakam with 37 Points vs. Milwaukee Bucks nba.com - April 24 at 12:29 AM
	Pascal Siakam scores and draws the foul sports.yahoo.com - April 24 at 12:29 AM
	Pascal Siakam puts up 37 as Pacers pull level with Bucks reuters.com - April 24 at 12:29 AM
	Pascal Siakam helps the Pacers tie series up at 1-1 against Bucks hoopshype.com - April 24 at 12:29 AM
	Pascal Siakam leads resurgent Pacers offense in 125-108 victory that evens series with Bucks msn.com - April 24 at 12:29 AM
	Pascal Siakam Wows NBA Fans as Haliburton, Pacers Beat Lillard, Bucks Without Giannis bleacherreport.com - April 24 at 12:29 AM
	A Matt Damon And Pedro Pascal Movie Flop From 2017 Is Coming To Netflix In May forbes.com - April 23 at 7:29 PM
	Pascal Fratellia leaves Olympics role at EBU tvbeurope.com - April 23 at 9:28 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Wendy’s Stock Could Be Your Best Passive Income Stock
April 9, 2024 7:45 AM
View Wendy’s Stock Could Be Your Best Passive Income Stock
Breakout Alert: Coinbase's Consolidation Is About To End
April 12, 2024 9:45 AM
View Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
April 12, 2024 10:00 AM
View You Can Follow BlackRock’s Market View for Your Money
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
April 15, 2024 7:40 AM
View Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
Is Zoom Video Stock Getting Too Cheap to Pass Up?
April 24, 2024 7:06 AM
View Is Zoom Video Stock Getting Too Cheap to Pass Up?

All Headlines

Company Descriptions

Armata Pharmaceuticals

NYSEAMERICAN:ARMP

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

MOTIF BIO PLC/S

NASDAQ:MTFB

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

Overlay Shares Core Bond ETF

NYSEARCA:OVB

The Overlay Shares Core Bond ETF (OVB) is an exchange-traded fund that is based on the Bloomberg US Aggregate Bond index. The fund is actively managed to provide exposure to U.S. Investment-grade bonds combined with a U.S OVB was launched on Sep 30, 2019 and is managed by Overlay Shares.

Pascal Biosciences

CVE:PAS

Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial